Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors

With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Zhao, Peng, Peng, Ling, Wu, Wei, Zheng, Yi, Jiang, Weiqin, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Ma, Ruobing, Wang, Liping, Yao, Ming, Wang, Kai, Fang, Weijia, Wu, Liming
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Precision Medicine Clinic: Molecular Tumor Board
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/
https://ncbi.nlm.nih.gov/pubmed/30679319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars